Ankyra Therapeutics Presents Preliminary Phase 1 Canine Clinical Data Evaluating cANK-101 to Treat Advanced Malignant Melanoma in Dogs streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ ImmVira announced to appoint Dr. Howard L. Kaufman as Consulting Medical Advisor. Dr. Kaufman s expertise in scientific research and clinical.
CAMBRIDGE, Mass., August 07, 2023 Ankyra Therapeutics, a pre-clinical biotechnology company developing targeted immune potentiating agents for the treatment of cancer, today announced the appointment of Robert V. Tighe, as chief scientific officer. He joined the team on July 10, 2023 and brings considerable immuno-oncology drug development experience to the company.
Preliminary data of anchored canine IL-12 (cANK-101) in dogs with malignant melanoma demonstrates tolerable safety and early signs of biologic activity. Human ANK-101 is an IL-12-based anchored immunotherapy with IND submission planned for late 2023BOSTON (BUSINESS WIRE) Ankyra Therapeutics, a pre-clinical-stage o.
BOSTON (BUSINESS WIRE) Ankyra Therapeutics is pleased to announce that it has entered into a formal research collaboration with the College of Veterinary Medicine at the University of Illinois Urbana-Champaign. Ankyra is developing a novel anchored immunotherapy platform that allows retention of immune-oncology dr.